CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project investigates the effects of a novel drug, compound 21, and melatonin on cardiovascular remodeling in hypertensive rats. By targeting the type 2 angiotensin receptor, the study aims to enhance treatment strategies for hypertension and related cardiovascular diseases.
Cardiovascular (CV) diseases are the major source of morbidity and mortality in the EU with annual costs of € 169 billion.
The control of hypertension and prevention of left ventricular (LV) hypertrophy and fibrosis, which could interrupt the CV continuum, still remain insufficient world-wide. A substantial part of current therapies modulate the renin-angiotensin system (RAS) and decrease the unfavorable stimulation of angiotensin type 1 receptors (AT1R).
Results of the host group indicate that…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
